InvestSMART

Cleo Diagnostics Ltd (ASX: COV) - Share Price

Current share price for COV : $0.345 0.01 (2.99%)+

Cleo Diagnostics Limited (COV) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a biotechnology company that commercializes novel technology for the detection of ovarian cancers.

COV General Information +

ASX Code COV
Website http://www.cleodx.com
Industry/Sector Health Care Equipment
Market Cap ($M) 47
COV Share Price $0.345
Day High $0.360
Day Low $0.335
Last Close $0.335
COV Share Price Movement $0.01 ( 2.99% )
Prices as at 16:40, 31 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

How COV Plays a Part in Australian ETF Strategies

Cleo Diagnostics Ltd (COV) is held across 12 ETFs spanning strategies that include health care equipment exposure . Its weighting in those funds means performance can have an outsized influence - when COV moves, funds like DJRE, REIT, GLPR, ESGI and VEQ that hold it can move with it.

For more concentrated exposure, ETFs such as DJRE (SPDR Dow Jones Global Real Estate ESG Fund) allocate about 0.2% to COV , while the average exposure across all 12 ETFs that hold it is around 0.1% .

Top ETF holdings

COV Direct vs. ETF Alternatives

How does holding Cleo Diagnostics Ltd (COV) shares directly compare to ETFs that include it?

COV Direct
DJRE
ASX 		REIT
ASX 		GLPR
ASX 		ESGI
ASX 		VEQ
ASX
Holdings 1 company 220 holdings 299 holdings 303 holdings 144 holdings 1,192 holdings
Risk Profile High Medium Medium Medium Medium Medium
Asset Class Share Property & Infrastructure Property & Infrastructure Property & Infrastructure Equities Equities
Annual Cost Brokerage only 0.2% p.a. 0.2% p.a. 0.15% p.a. 0.55% p.a. 0.35% p.a.
Approx. Yield - 2.66% 4.34% 4.86% 2.75% 2.17%
Latest Franking - 0% 0% 0% 0% 0%

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not COV's direct yield.

Cleo Diagnostics Ltd (COV) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Cleo Diagnostics Ltd (COV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Cleo Diagnostics Ltd (COV) price-sensitive announcements

COV - Quarterly activities and cashflow report
Cleo Diagnostics Ltd (ASX:COV) has been progressing towards the U.S. FDA submission and co
Cleo Diagnostics Ltd (COV)
29 Jul 2026 | 9:39 AM
COV - CLEO Enters Analytical Validation Phase
Cleo Diagnostics Ltd (ASX:COV) has announced its entry into the analytical validation phas
Cleo Diagnostics Ltd (COV)
13 Jul 2026 | 9:10 AM
COV - CLEO Establishes U.S. Reimbursement Pathway
Cleo Diagnostics Ltd (ASX:COV) has outlined a strategic plan for entering the U.S. market
Cleo Diagnostics Ltd (COV)
20 May 2026 | 9:25 AM
COV - Quarterly activities and cashflow report
Cleo Diagnostics Ltd, trading on the ASX under the ticker COV, provided its quarterly repo
Cleo Diagnostics Ltd (COV)
29 Apr 2026 | 9:32 AM

Cleo Diagnostics Ltd (COV) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
 Health Care $47 Quarterly activities and cashflow report 29 Jul 2026 9:39AM $0.320 $0.345 risen by 7.81%
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
 Health Care $47 CLEO Enters Analytical Validation Phase 13 Jul 2026 9:10AM $0.510 $0.345 fallen by 32.35%
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
 Health Care $47 Change in Director's Interest Notice 7 Jul 2026 4:41PM $0.495 $0.345 fallen by 30.30%
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
 Health Care $47 Cleansing Notice 28 May 2026 4:18PM $0.585 $0.345 fallen by 41.03%
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
 Health Care $47 Application for quotation of securities - COV 28 May 2026 4:12PM $0.585 $0.345 fallen by 41.03%
Cleo Diagnostics Ltd (COV)
ORDINARY FULLY PAID
 Health Care $47 CLEO Establishes U.S. Reimbursement Pathway 20 May 2026 9:25AM $0.635 $0.345 fallen by 45.67%

COV Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$4.00 -$3.10 -2.80% 0.00 0.00 0.00% 0.0%
2024A -$3.76 -$3.20 -51.40% 0.00 0.00 0.00% 0.0%
2023A -$1.73 -$6.60 21,866.70% 0.00 0.00 0.00% 0.0%

COV Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Cochlear Limited (COH) $7,992M 0.0171 -0.1894 0.0615 20.4201 25.1917 23.7314 3.52% 2.84% 2.95%
Cleo Diagnostics Ltd (COV) $46M -0.0281 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Fisher & Paykel Healthcare Corporation Limited (FPH) $20,109M 0.1388 0.1421 0.1883 51.7768 45.3330 38.1504 1.27% 1.36% 1.54%
ResMed Inc. (RMD) $17,969M 0.3087 9.7744 0.0595 208.0468 19.3093 18.2251 1.11% 1.16% 1.22%

COV Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 7.60 0.00
Market 0.32 12.80 1.13 0.61
Sector 0.70 19.60 1.58 1.76

COV Directors

Name Position Start Date
Dr Richard Allman Chief Executive Officer, Managing Director 10 Oct 2022
Dr Andrew Nicholas Stephens Chief Scientific Officer, Executive Director 19 Sep 2022
Professor Thomas Jobling Lead Medical Advisor, Non-Executive Director 21 Dec 2022
Mr Adrien Michele Wing Non-Executive Chairman, Non-Executive Director 11 Aug 2022
Ms Lucinda Nolan Non-Executive Director 2 Mar 2023

Cleo Diagnostics Ltd (COV) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
14 Apr 2009 MOORE, John Transfer Direct Shares 209,420 $0.054 $11,308.680
14 Apr 2009 MOORE, John Buy Indirect Shares 40,760 $0.054 $2,201.040
18 Mar 2009 MOORE, John Buy Direct Shares 130,000 $0.042 $5,400.000

See all changes in directors' interest & trades for Cleo Diagnostics Ltd (COV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

COV Management

Name Position
Pauline M Moffatt Company Secretary

COV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Cleo Diagnostics Ltd (COV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
14,250,000 (11.09%) Michelle Wing
9,125,000 (7.10%) Richard Vom
7,189,140 (5.59%) Hudson Institute Investment Holdings Pty Ltd

COV Calendar of Events

Date Event
24 February 2027 Report (Interim)
25 August 2026 Report (Annual)
25 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.